Key Details
Price
$0.49Annual ROE
-387.35%Beta
1.51Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Aug 14, 2023Recent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
July 01, 2024Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
BRANFORD, Conn. , Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended September 30, 2024 and provided a business update.
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024, and provided a business update. Q2 2024 and Recent Business Highlights Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025. With the recent financing, the company anticipates announcing m.
Azitra (NYSEMKT: AZTR ) stock is taking off on Tuesday after the early-stage biopharmaceutical company provided investors with updates on its patents. This covers the company's filaggrin-secreting strain of Staphylococcus epidermidis.
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that management will present at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego, California. The presentation will take place on Wednesday, June 5, 2024 at 12:00 PM PDT in Theater 3 at the San Diego Convention Center. The corporate update will highlight Azitra's updates.
Azitra, Inc. (NYSE American: AZTR), a biopharmaceutical company specializing in precision dermatology treatments, shared preclinical data from its platform and pipeline. The findings will be presented on May 17, 2024, in two oral sessions discussing the use of Staphylococcus epidermidis for treating EGFR inhibitor-induced dermal toxicity and cutaneous delivery.
Azitra (NYSEMKT: AZTR ) stock is falling on Wednesday after the pre-clinical biopharmaceutical company announced details for a public share offering. Azitra is selling 16,667,000 shares of AZTR stock for 30 cents per share.
FAQ
- What is the primary business of Azitra?
- What is the ticker symbol for Azitra?
- Does Azitra pay dividends?
- What sector is Azitra in?
- What industry is Azitra in?
- What country is Azitra based in?
- When did Azitra go public?
- Is Azitra in the S&P 500?
- Is Azitra in the NASDAQ 100?
- Is Azitra in the Dow Jones?
- When was Azitra's last earnings report?
- When does Azitra report earnings?
- Should I buy Azitra stock now?